Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine

Cellular and Molecular Immunology

Volumn 7, Issue 2, 2010, Pages 116-122

  Yang, Penghui ^a   Xing, Li ^a   Tang, Chong ^a   Jia, Weihong ^a   Zhao, Zhongpeng ^a   Liu, Kun ^a   Gao, Xiao ^a   Wang, Xiliang ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

BALB c mice; Influenza; Influenza A (H1N1); Split vaccine

Indexed keywords

ALUMINUM HYDROXIDE; GAMMA INTERFERON; HEMAGGLUTININ; INFLUENZA VACCINE; INTERLEUKIN 4; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA VIRUS A H1N1; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PANDEMIC; PRIMATE;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEMAGGLUTININS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; KINETICS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RATS; RATS, SPRAGUE-DAWLEY;

INFLUENZA A VIRUS; MUS; PRIMATES; RATTUS;

EID: 77749283655     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2009.116     Document Type: Article

References (35)

1. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009; 459: 1122-1125.
2. Naffakh N, Van Der Werf S. April 2009: an outbreak of swine-origin influenza A (H1N1) virus with evidence for human-to-human transmission. Microbes Infect 2009; 11: 725-728.
3. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009; 27: 1889-1897.
4. Hovden AO, Brokstad KA, Major D, Wood J, Haaheim LR, Cox RJ. A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice. Influenza Other Respi Viruses 2009; 3: 21-28.
5. Huber VC, Thomas PG, McCullers JA. A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine 2009; 27: 1192-1200.
6. Chen Z, Santos C, Aspelund A, Gillim-Ross L, Jin H, Kemble G et al. Evaluation of live attenuated influenza a virus h6 vaccines in mice and ferrets. J Virol 2009; 83: 65-72.
7. Murakami S, Iwasa A, Iwatsuki-Horimoto K, Ito M, Kiso M, Kida H et al. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine 2008; 26: 6398-6404.
8. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N et al. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine - preliminary report. N Engl J Med 2009
9. Webster RG, Kawaoka Y, Taylor J, Weinberg R, Paoletti E. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 1991; 9: 303-308.
10. Suguitan AL Jr, McAuliffe J, Mills KL, Jin H, Duke G, Lu B et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006; 3: e360.
11. Collin N, De Radiguès X, Kieny MP, the World Health Organization H1N1 Vaccine Task Force. New influenza A (H1N1) vaccine: how ready are we for large-scale production? Vaccine 2009; in press.
12. Macdonald N, Hébert PC, Stanbrook MB, Flegel K, Attaran A, Eggertson L. H1N1 influenza vaccine: global access for a global problem. CMAJ 2009; in press.
13. Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009; 58: 521-524.
14. Michaelis M, Doerr HW, Cinatl J JrNovel swine-origin influenza A virus in humans: another pandemic knocking at the door. Med Microbiol Immunol 2009; 198: 175-183.
15. Butler D. Vaccine decisions loom for new flu strain. Nature 2009; 459: 144-145.
16. Enserink M, Kaiser J. Swine flu outbreak. Devilish dilemmas surround pandemic flu vaccine. Science 2009; 324: 702-705.
17. Shetty P. Preparation for a pandemic: influenza A H1N1. Lancet Infect Dis 2009; 9: 339-340.
18. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605-2615.
19. World Health Organization. Situation updates - influenza A (H1N1). Geneva: World Health Organization, 2009. Available from: http://www.who.int/csr/ disease/swineflu/ updates/en/index.html.
20. Du N, Li W, Li Y, Liu S, Sui Y, Qu Z et al. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses. Vaccine 2008; 26: 2912-2918.
21. Jin R, Lv Z, Chen Q, Quan Y, Zhang H, Li S et al. Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of Bombyx mori. PLoS One 2008; 3: e3933.
22. Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R, Chen WH et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009; 27: 5091-5095.
23. Xiao W, Du L, Liang C, Guan J, Jiang S, Lustigman S et al. Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines. Vaccine 2008; 26: 5022-5029.
24. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354: 1343-1351.
25. Van Der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, Oxford J. Animal models in influenza vaccine testing. Expert Rev Vaccines 2008; 7: 783-793.
26. Tripp RA, Tompkins SM. Animal models for evaluation of influenza vaccines. Curr Top Microbiol Immunol 2009; 333: 397-412.
27. Barnard DL. Animal models for the study of influenza pathogenesis and therapy. Antiviral Res 2009; 82: A110-A122.
28. Matsuoka Y, Lamirande EW, Subbarao K. The mouse model for influenza. Curr Protoc Microbiol 2009; Chapter 15: Unit 15G.3.
29. Chen Z, Santos C, Aspelund A, Gillim-Ross L, Jin H, Kemble G et al. Evaluation of live attenuated influenza a virus h6 vaccines in mice and ferrets. J Virol 2009; 83: 65-72.
30. Vajdy M, Baudner B, del Giudice G, O'Hagan D. A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. Clin Immunol 2007; 123: 166-175.
31. Beigel JH, Voell J, Huang CY, Burbelo PD, Lane HC. Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J Infect Dis 2009; 200: 501-508.
32. Romanova J, Krenn BM, Wolschek M, Ferko B, Romanovskaja-Romanko E, Morokutti A et al. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One 2009; 4: e5984.
33. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, BardelliMet al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009; 106: 7962-7967.
34. Tada Y. Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza Other Respi Viruses 2008; 2: 261-266.
35. Hauge S, Madhun AS, Major D, Brokstad KA, Vogel FR, Zambon M et al. The immunogenicity of a cell-derived H7N1 split influenza virion vaccine in mice. Scand J Immunol 2009; 69: 576-578.